Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Ovarian
Descriptor: Met expression


Reference Number: 106
Huntsman, D., Resau, J. H., Klineberg, E. & Auersperg, N. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 155, 343-8. (1999).
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 436
Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer. 15, 618-23 (2005)
PubMed link      E-mail link

Reference Number: 731
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 17, 57-67 (2009)
PubMed link      E-mail link

Reference Number: 826
Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 18, 976-84 (2008)
PubMed link      E-mail link

Reference Number: 827
Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67, 1670-9 (2007)
PubMed link      E-mail link

Reference Number: 828
Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 12, 1-10 (2010)
PubMed link      E-mail link

Reference Number: 829
Tang MK, Zhou HY, Yam JW, Wong AS. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia. 12, 128-38 (2010)
PubMed link      E-mail link

Reference Number: 830
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 16, 1119-28 (2010)
PubMed link      E-mail link

Reference Number: 991
Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene30, 1566-76 (2011)
PubMed link      E-mail link

Reference Number: 1117
Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 24, 1146-55 (2011)
PubMed link      E-mail link

Reference Number: 1155
Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther. 11, 492-502 (2012)
PubMed link      E-mail link

Reference Number: 1171
Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol. 25, 122-30 (2012)
PubMed link      E-mail link

Reference Number: 1197
Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, Nikitin AY. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle. 10, 3834-40 (2011)
PubMed link      E-mail link

Reference Number: 1593
Davies S, Holmes A, Lomo L, Steinkamp MP, Kang H, Muller CY, Wilson BS. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol. 33, 402-10 (2014)
PubMed link      E-mail link

Reference Number: 1644
Liu S, Zheng Y, Volpi D, El-Kasti M, Klotz D, Tullis I, Henricks A, Campo L, Myers K, Laios A, Thomas P, Ng T, Dhar S, Becker C, Vojnovic B, Ahmed AA. Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. Cancer. 121, 202-13 (2015)
PubMed link      E-mail link

Reference Number: 1695
Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 5, 4855-67 (2014)
PubMed link      E-mail link

Reference Number: 1713
Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. Int J Cancer. 137, 289-98 (2015)
PubMed link      E-mail link

Reference Number: 1737
Tang C, Jardim DL, Hong D. MET in ovarian cancer: metastasis and resistance? Cell Cycle. 13, 1220-1 (2014)
PubMed link      E-mail link

Reference Number: 1866
Patterson SD, Rossi JM, Paweletz KL, Fitzpatrick VD, Begley CG, Busse L, Elliott S, McCaffery I. Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues. PLoS One. 10, e0122149 (2015)
PubMed link      E-mail link

Reference Number: 1867
Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 6, 11342-56 (2015)
PubMed link      E-mail link